Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications

Cells expressing FLT3/ITD mutations exhibit elevated repair errors generated through alternative NHEJ pathways: implications for genomic instability and therapy

(2010) J. Fan et al.   BLOOD

Cell Signaling by Receptor Tyrosine Kinases

(2010) Mark A. Lemmon et al.   CELL

Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3

(2010) Thomas Fischer et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations in acute promyelocytic leukemia: A systematic review

(2010) Amer Beitinjaneh et al.   LEUKEMIA RESEARCH

DNMT3AMutations in Acute Myeloid Leukemia

(2010) Timothy J. Ley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeted Signal Transduction Therapies in Myeloid Malignancies

(2010) Emma Scott et al.   Current Oncology Reports

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

(2009) P. P. Zarrinkar et al.   BLOOD

Comprehensive analysis of cooperative gene mutations between class I and class II inde novoacute myeloid leukemia

(2009) Yuichi Ishikawa et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

RUNX1 and its fusion oncoprotein derivative, RUNX1-ETO, induce senescence-like growth arrest independently of replicative stress

(2009) K Wolyniec et al.   ONCOGENE

Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML

(2008) Z. Zeng et al.   BLOOD

Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100

(2008) B. Nervi et al.   BLOOD

Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML

(2008) A. Sallmyr et al.   BLOOD

Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens

(2008) Keith Pratz et al.   LEUKEMIA & LYMPHOMA